Hepatic steatosis is the most common emerging liver disease occurring in the US population, and is caused by an abnormal accumulation of lipids within hepatocytes. The Liver X receptor alpha (LXR?) is a major transcription factor for regulating the genes promoting de novo lipogenesis, specifically biosynthesis of fatty acids (FAs) and triglycerides (TGs), which contributes to hepatic steatosis. Recent studies from my laboratory suggest that Nogo-B receptor (NgBR) plays a previously unrecognized role in regulating LXR??nuclear translocation. Our new findings support the concept that NgBR inhibits nuclear translocation of LXR?? and that NgBR expression is essential for preventing LXR??dependent lipogenesis. However, the molecular mechanisms by which NgBR regulates LXR? translocation remain unknown. This proposal is designed to fill gaps in our knowledge concerning the role of NgBR in regulating LXR? translocation, and to determine if blocking LXR? nuclear translocation is sufficient to prevent hepatic steatosis. Preliminary results show that NgBR expression is decreased in fatty livers, and NgBR hepatocyte-specific knockout (hepKO) mice have increased FA and TG content in the liver. These data suggest that a decrease in NgBR expression induces LXR? nuclear translocation, which lead to hepatic steatosis. Based on these findings and previous reports, we hypothesize that NgBR regulates LXR? nuclear translocation in hepatocytes through the LKB1-AMPK pathway, and disruption of this regulation leads to hepatic steatosis. Our overall objectives are to elucidate the molecular mechanisms by which NgBR prevents LXR? nuclear translocation and the roles NgBR plays in the pathogenesis of hepatic steatosis. Delineating the mechanisms by which NgBR regulates LXR? nuclear translocation will allow us to develop new therapeutic strategies for preventing hepatic steatosis. Accordingly, we will test our hypothesis in the three specific aims.
Aim 1 : Determine the roles of NgBR-LKB1 interaction in regulating AMPK activation.
Aim 2 : Determine the molecular mechanism by which the NgBR- LKB1-AMPK pathway regulates LXR? phosphorylation and nuclear translocation.
Aim 3 : Determine the roles NgBR plays in the pathogenesis of hepatic steatosis and steatohepatitis; and, determine the extent to which preventing LXR? nuclear translocation ameliorates hepatic steatosis. The proposed studies will reveal new therapeutic strategies for preventing and/or reducing hepatic steatosis and thus have a significant impact on the field of hepatology. If successful, we will be the first to show how NgBR signaling regulates the molecular mechanisms driving hepatic steatosis. Our studies will lead to new discoveries that will greatly improve the health of US citizens and others suffering from hepatic steatosis. Our studies will reveal new concepts and ideas that can be used to develop therapies for treating hepatic steatosis. Accordingly, the translational potential of this application is strong and highly relevant to NIH's mission.

Public Health Relevance

Abnormal accumulation of lipids in hepatocytes causes hepatic steatosis, an emerging liver disease in the US population. The proposed research will lead to new discoveries that will greatly improve the health of US citizens and others suffering from hepatic steatosis by revealing new concepts and ideas that can be used to develop therapies for the treatment of hepatic steatosis. Thus, the proposed research is relevant to NIH's mission that pertains to developing new approaches/fundamental knowledge that will help to reduce the burdens of human disability.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK112971-01
Application #
9285116
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Doo, Edward
Project Start
2017-04-01
Project End
2022-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Medical College of Wisconsin
Department
Surgery
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Holcomb, Joshua; Doughan, Maysaa; Spellmon, Nicholas et al. (2018) SAXS analysis of a soluble cytosolic NgBR construct including extracellular and transmembrane domains. PLoS One 13:e0191371
Ma, Chuanrui; Zhang, Wenwen; Yang, Xiaoxiao et al. (2018) Functional interplay between liver X receptor and AMP-activated protein kinase ? inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy. Br J Pharmacol 175:1486-1503
Zhang, Wenwen; Yang, Xiaoxiao; Chen, Yuanli et al. (2018) Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. Biochim Biophys Acta Mol Cell Biol Lipids 1863:177-190
Liu, Ying; Wei, Zhuo; Ma, Xingzhe et al. (2018) 25-Hydroxycholesterol activates the expression of cholesterol 25-hydroxylase in an LXR-dependent mechanism. J Lipid Res 59:439-451
Tang, Jinglong; Chen, Zhiyun; Sun, Baoyun et al. (2016) Polyhydroxylated fullerenols regulate macrophage for cancer adoptive immunotherapy and greatly inhibit the tumor metastasis. Nanomedicine 12:945-954